Biopharmaceuticals, especially therapeutic monoclonal antibodies(mAbs), are mainly produced in mammalian cell culture systems. Glycosylation is a critical quality attribute of mAbs, which has a significant impact on their biological activity, pharmacokinetics, half-life, and immunogenicity. Therefore, in order to better control the quality of glycosylation modification, the glycosylation process of mAbs must be regulated and monitored throughout the culture process of mammalian cells. This review focuses on the engineering of mammalian cells, optimization of cell culture processes and culture media, glycosylation regulators, mathematical models and omics technologies. And it introduces the technological progress achieved in the regulation of glycosylation modification of monoclonal antibodies during mammalian cell culture.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |